Evidence map›Paper›PMID 41465338›Full record

ArticleInternational journal of molecular sciences2025

Soloxolone

Arseny D Moralev, Aleksandra V Sen'kova, Alina A Firsova, Daria E Solomina, Artem D Rogachev, Oksana V Salomatina, Nariman F Salakhutdinov, Marina A Zenkova, Andrey V Markov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Arseny D MoralevInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrent'ev Ave., 8, 630090 Novosibirsk, Russia.ORCID 0009-0001-0410-5403
Aleksandra V Sen'kovaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrent'ev Ave., 8, 630090 Novosibirsk, Russia.ORCID 0000-0001-5729-9910
Alina A FirsovaFaculty of Natural Sciences, Novosibirsk State University, Pirogov St. 2, 630090 Novosibirsk, Russia.
Daria E SolominaFaculty of Natural Sciences, Novosibirsk State University, Pirogov St. 2, 630090 Novosibirsk, Russia.
Artem D RogachevFaculty of Natural Sciences, Novosibirsk State University, Pirogov St. 2, 630090 Novosibirsk, Russia.ORCID 0000-0002-3338-8529
Oksana V SalomatinaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrent'ev Ave., 8, 630090 Novosibirsk, Russia.
Nariman F SalakhutdinovN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrent'ev Ave., 9, 630090 Novosibirsk, Russia.
Marina A ZenkovaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrent'ev Ave., 8, 630090 Novosibirsk, Russia.ORCID 0000-0003-4044-1049
Andrey V MarkovInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrent'ev Ave., 8, 630090 Novosibirsk, Russia.ORCID 0000-0001-7569-9555

Funding

Russian Science Foundation 23-14-00374Russian state-funded project for ICBFM SB RAS 125012300659-6
6 · The paper itself

Abstract

Multidrug resistance (MDR) remains a significant obstacle to effective cancer chemotherapy, primarily due to overexpression of P-glycoprotein (P-gp), which reduces intracellular accumulation of cytotoxic drugs. This study evaluated the pharmacological potential of the glycyrrhetinic acid derivative soloxolone N-3-(dimethylamino)propylamide (Sol-DMAP) as a biocompatible P-gp inhibitor with hepatoprotective properties. Using a murine model of P-gp-overexpressing RLS40 lymphosarcoma, we demonstrated that Sol-DMAP significantly enhanced the antitumor efficacy of doxorubicin (DOX) by increasing its intratumoral concentration 4.7-fold without enhancing systemic toxicity. Independently, Sol-DMAP exhibited direct antitumor activity, reducing tumor growth in vivo and inducing apoptosis and G1-phase arrest in RLS40 cells in vitro. In addition, Sol-DMAP mitigated DOX-induced hepatic injury by reducing necrotic and dystrophic changes in liver tissue and restoring heme oxygenase 1 (Hmox1) expression. Further studies in HepG2 cells confirmed that Sol-DMAP activated the NRF2-dependent antioxidant response, upregulating

Indexed as

Chemical and Drug Induced Liver InjuryDoxorubicinAnimalsAntineoplastic AgentsApoptosisATP Binding Cassette Transporter, Subfamily B, Member 1Cell Line, TumorCell ProliferationDrug Resistance, NeoplasmHeme Oxygenase-1Hep G2 CellsHumansLiverMaleMiceNF-E2-Related Factor 2Antineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1DoxorubicinHeme Oxygenase-1NF-E2-Related Factor 2doxorubicinglycyrrhetinic acidhepatoprotectionlymphosarcomamultidrug resistanceNRF2 signalingoxidative stressP-glycoproteinsoloxolone

Identifiers

PMID41465338
PMCPMC12732862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.